menu
    • menu
    [{"orgOrder":0,"company":"Ramon Gorter","sponsor":"ZonMw | Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Co-amoxiclav","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ramon Gorter","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ramon Gorter \/ ZonMw | Amsterdam UMC, VUmc","highestDevelopmentStatusID":"11","companyTruncated":"Ramon Gorter \/ ZonMw | Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"ClinPharmInvest","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Co-amoxiclav","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmtechnology \/ ClinPharmInvest","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ ClinPharmInvest"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"ClinPharmInvest","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Co-amoxiclav","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmtechnology \/ ClinPharmInvest","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ ClinPharmInvest"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"The research foundation of Copenhagen University Hospital, Rigshospitalet | Copenhagen Health Science Partners | Innovation Fund Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Co-amoxiclav","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ The research foundation of Copenhagen University Hospital, Rigshospitalet | Copenhagen Health Science Partners | Innovation Fund Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Rigshospitalet \/ The research foundation of Copenhagen University Hospital, Rigshospitalet | Copenhagen Health Science Partners | Innovation Fund Denmark"}]

    Find Clinical Drug Pipeline Developments & Deals for Clamentin

    Menu

    Clamentin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rigshospitalet

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            Rigshospitalet

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : The research foundation of Copenhagen University Hospital, Rigshospitalet | Copenhagen Health Science Partners | Innovation Fund Denmark

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral-only Antibiotics for Bone and Joint Infections in Children

                            Details : Co-Amoxiclav is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteomyelitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2020

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : The research foundation of Copenhagen University Hospital, Rigshospitalet | Copenhagen Health Science Partners | Innovation Fund Denmark

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmtechnology

                            Belarus arrow
                            ACI Convention
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augm...

                            Details : Clavamox is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 11, 2018

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmtechnology

                            Belarus arrow
                            ACI Convention
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Bela...

                            Details : Clavamox is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 06, 2018

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ramon Gorter

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            Ramon Gorter

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : ZonMw | Amsterdam UMC, VUmc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Chi...

                            Details : Augmentin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Appendicitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 29, 2016

                            Lead Product(s) : Co-amoxiclav

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : ZonMw | Amsterdam UMC, VUmc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth